On Monday, ten ships passed through the Strait of Hormuz. A month ago, before the latest escalation between the United States and Iran, the daily figure was closer to 130. That collapse, recorded by the maritime tracking firm Kpler, has drawn attention mostly for what it means for oil prices, which climbed to $87 a barrel before easing after President Trump abandoned his proposed shipping levy. Less attention has gone to a quieter consequence: a meaningful share of the raw material behind Britain's medicine supply passes through, or depends on refining and logistics anchored in that same corridor.

This is not a new vulnerability. It is an old one being tested again. Since 2023, successive DHSC resilience reviews have identified active pharmaceutical ingredient sourcing as one of the more fragile links in the UK's medicines supply chain, with production concentrated in a small number of hubs in India and the Gulf that rely on the Strait for both incoming feedstock and outbound shipment. The department has spoken of building resilience into that system. What has actually changed in the underlying geography of sourcing is considerably less clear.

Britain has already had two consecutive winters of documented shortages, spanning HRT preparations, ADHD medications, certain antibiotics and epilepsy treatments. Ministers have tended to describe these episodes as temporary, manageable, and unconnected to any single structural cause. That framing has always been generous. It becomes harder to sustain when a corridor responsible for a significant share of API logistics is operating at under a tenth of its normal throughput, with insurers and shippers openly describing the risk environment as too unstable to price with confidence.

The lag matters here. Disruption at the point of shipment does not show up in NHS trusts or community pharmacies immediately. It surfaces weeks later, once existing stock is drawn down and the Medicine Supply Chain resilience programme's early warning mechanisms begin flagging gaps that trusts had not anticipated. If the current pattern of strikes and countermeasures persists even for a matter of weeks, that lag suggests the visible effects on UK shelves may not appear until autumn, by which point the political conversation may have moved on from Iran entirely.

This exposes something uncomfortable about how medicines security has actually been pursued since the pandemic. The rhetoric has consistently outpaced the structural change. Reshoring generic manufacturing to the UK has been discussed at length, but the pricing environment under the Voluntary Scheme for branded medicines, and its equivalent pressures on generics margins, makes Britain a commercially unattractive location for exactly the kind of production the resilience strategy claims to want onshore. Manufacturers have said as much in consultations. The incentive structure has not moved to match the stated ambition.

None of this means the current disruption will necessarily produce a domestic shortage crisis. Shipping routes can stabilise quickly, and the war's trajectory remains genuinely unpredictable, as Trump's reversal on the shipping fee itself demonstrated. But the test this moment offers is not really about whether shortages materialise this time. It is about whether the institutional machinery built since 2023, the resilience programmes, the supply chain mapping, the ministerial assurances, produces a materially different outcome from the shortages of the past two winters, or simply reproduces the same pattern with a different geopolitical trigger.

If ministers are asked in the coming weeks whether the NHS medicines supply is secure against Gulf shipping disruption, the honest answer would acknowledge that resilience has been treated largely as a monitoring exercise rather than a sourcing one. We will learn more about the fundamentals of Britain's drugs security plan than any of the studies that have been published thus far if we observe whether it changes or if the reply is once again restricted to assurance followed by a chain of supply lag that nobody fully anticipated.